Le Lézard
Classified in: Health, Science and technology
Subject: Contract/Agreement

VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs


VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates.

Under the terms of the collaboration agreement, VeriSIM will leverage its proprietary BIOiSIMtm platform and Translational Indextm approach to reduce the number of outsourced preclinical experiments and help de-risk R&D decisions early-on to ensure expedited development of novel, safe and highly efficacious drugs.

VeriSIM will engage Mayo Clinic physician researchers in key disease areas including oncology, hematology, bone/joint-disorders, and neurological diseases.

"This collaboration will explore the full potential of our combined approach to developing best-in-class drug candidates to serve patients' unmet needs," said Dr. Jo Varshney, founder and CEO of VeriSIM Life. "We are excited to expand our common mission and work with the world's top research hospital and its drug discovery programs."

Dr. Jo Varshney, DVM and PhD, founded VeriSIM Life in 2017 alongside a cross-functional team of pharmaceutical scientists, software engineers and AI/ML and simulation experts. VeriSIM offers unprecedented value for the drug development industry by reducing the number of drug compounds likely to treat or cure specific illnesses and diseases.

Mayo Clinic participated in VeriSIM's Series A financing and has financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About VeriSIM Life

VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The program not only reduces the time and cost of drug discovery and development, it also greatly reduces the need for animal testing that, in the vast majority of cases, does not translate to humans.

For more information about VeriSIM Life, follow them on Twitter at @VeriSIMlife, visit www.verisimlife.com or email [email protected].


These press releases may also interest you

at 08:20
In celebration of National Doctors' Day on March 30, patients across the country are sharing personal stories about how their MDVIP-affiliated primary care physician has made a difference in their life. MDVIP collected and will deliver to its network...

at 08:17
AMIGOS FOR KIDS, a Miami nonprofit organization founded in 1991, is dedicated to preventing child abuse and neglect by valuing children, strengthening families and educating communities. ...

at 08:15
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount....

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...



News published on and distributed by: